Keyphrases
Acute Leukemia
10%
Allogeneic Bone Marrow Transplantation
12%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
17%
Alternative Donor
16%
Alternative Donor Transplantation
7%
Blood or Marrow Transplantation
7%
Bone Marrow Transplantation
24%
Confidence Interval
10%
Cumulative Incidence
14%
Cyclophosphamide
9%
Engraftment
7%
Event-free Survival
8%
Graft Failure
8%
Graft-versus-host Disease (GvHD)
60%
Graft-versus-host Disease Prophylaxis
7%
Haploidentical
11%
Haploidentical BMT
7%
Haploidentical Donor
10%
Haploidentical Transplantation
38%
Hematological Malignancies
23%
Hematopoietic Cell Transplantation
8%
High Dose
11%
High Risk
9%
HLA Matching
20%
HLA-haploidentical
28%
HLA-matched Donor
8%
Human Leukocyte Antigen
10%
Marrow Transplantation
6%
Matched Related
10%
Minimal Residual Disease
10%
Myeloablative
16%
Myeloablative Conditioning
15%
Myelodysplastic Syndrome
8%
Non-relapse Mortality
12%
Nonmyeloablative
19%
Overall Survival
15%
Pediatric
33%
Pediatric Patients
9%
Post-transplantation Cyclophosphamide (PTCy)
66%
Pretransplant
12%
Reduced-intensity Conditioning
8%
Relapsed Lymphoma
6%
Relapsed or Refractory
6%
Severe Aplastic Anemia
18%
T-cell Replete
7%
Tacrolimus
8%
Total Body Irradiation
7%
Transplant-related Mortality
7%
Transplantation
6%
Young Adult Patients
14%
Medicine and Dentistry
Acute Graft Versus Host Disease
12%
Acute Leukemia
13%
Acute Lymphoblastic Leukemia
5%
Adolescent Medicine
5%
Alternative Donor
14%
Aplastic Anemia
9%
Bone Marrow Transplantation
45%
Cell Transplantation
13%
Chronic Graft Versus Host Disease
6%
Clinical Trial
7%
Computer Assisted Tomography
9%
Conditioning
7%
Cumulative Incidence
19%
Cyclophosphamide
53%
Disease
20%
Donor Lymphocyte Infusion
5%
Drug Megadose
19%
Engraftment
13%
Enteric Feeding
9%
Event Free Survival
9%
Graft Failure
15%
Graft Versus Host Reaction
35%
Haploidentical Transplantation
9%
Hematologic Malignancy
30%
Hematopoietic Stem Cell
13%
Hematopoietic Stem Cell Transplantation
24%
Hemoglobinopathy
7%
Human Leukocyte Antigen
5%
Immunosuppressive Treatment
5%
Matched Donor
6%
Minimal Residual Disease
11%
Myeloablative Conditioning
8%
Myelodysplastic Syndrome
5%
Neoplasm
6%
Nonmyeloablative Conditioning
8%
Nutritional Support
5%
Overall Survival
16%
Pediatrics
49%
Pediatrics Patient
8%
Platelet
5%
Predictive Factor
5%
Prophylaxis
6%
Sinusitis
7%
Symptom
7%
T Cell
11%
Transplantation
23%
Whole Body Radiation
11%
Immunology and Microbiology
Acute Graft Versus Host Disease
21%
Allogeneic Bone Marrow Transplantation
11%
Allogeneic Hematopoietic Stem Cell Transplantation
6%
Aplastic Anemia
18%
Bone Marrow Transplantation
82%
Cell Transplantation
16%
Chimera
6%
Chronic Graft Versus Host Disease
18%
Conditioning
44%
Cyclophosphamide
100%
Drug Megadose
27%
Engraftment
16%
Event Free Survival
10%
Graft-Versus-Host Disease
58%
Hematopoietic Cell
16%
Hematopoietic Stem Cell Transplantation
21%
Host
5%
Human Leukocyte Antigen
10%
Immune Reconstitution
5%
Lymphocyte
10%
Mycophenolic Acid
9%
Myeloid
10%
Natural Killer Cell
5%
Overall Survival
23%
Platelet
5%
Progression Free Survival
7%
Recurrence Free Survival
9%
T Cell
21%
Tacrolimus
11%
Transplant Procedure
32%